US EditionPublished • loading... • Updated
After Buying HUB and Partnering with Promega, MilliporeSigma Charts Growth Path in Organoids
Drug developers and their contract development and manufacturing organizations (CDMOs) moving away from animal testing—whether for financial, regulatory, or moral reasons—are increasingly finding an alternative in organoid models designed to uncover biological insights previously unattainable through traditional cell culture experiments or animal models. Merck KGaA, Darmstadt, Germany, and its U.S. and Canada Life Science business, MilliporeSigm…
1 Articles
1 Articles
After Buying HUB and Partnering with Promega, MilliporeSigma Charts Growth Path in Organoids
Drug developers and their contract development and manufacturing organizations (CDMOs) moving away from animal testing—whether for financial, regulatory, or moral reasons—are increasingly finding an alternative in organoid models designed to uncover biological insights previously unattainable through traditional cell culture experiments or animal models. Merck KGaA, Darmstadt, Germany, and its U.S. and Canada Life Science business, MilliporeSigm…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
